Core Viewpoint - The perception that myopia surgery completely eliminates myopia and prevents regression is incomplete, as myopia cannot be cured, and new myopia may develop if eye care is neglected [1][2] Group 1: Myopia Surgery Insights - Myopia surgery can help individuals become independent from glasses, with techniques such as corneal laser surgery (e.g., SMILE Pro) and intraocular lens surgery (e.g., ICL, V4C, V5) effectively improving vision [1] - Post-surgery, it is crucial to maintain long-term eye care, as improper habits like excessive screen time or rubbing the eyes can still negatively impact vision [1] Group 2: Vision Protection Recommendations - To protect vision, maintaining a regular schedule and avoiding prolonged screen time is essential, with the "20-20" rule recommended: take a 20-second break every 20 minutes of screen time, ideally looking at something 5 meters away [2] - There is currently no medical evidence supporting the effectiveness of myopia prevention patches or devices, and validated methods should be prioritized for myopia control [2] - Recommended strategies for myopia prevention include at least 2 hours of outdoor activity daily, using optical aids like OK lenses or prescription glasses under medical guidance, and considering low-concentration atropine under a doctor's advice [2]

Core Viewpoint - The effectiveness of products claiming to prevent myopia and improve vision, such as "myopia prevention patches" and "eye protection devices," lacks medical evidence and is not recommended by experts [1] Group 1: Expert Opinions - Dr. Zhou Xingtao from Fudan University emphasizes that there is currently no medical evidence supporting the effectiveness of these products, highlighting that myopia cannot be cured once it occurs [1] - The focus should be on validated methods for myopia prevention, rather than unproven products [1] Group 2: Recommended Prevention Methods - The first recommended method is lifestyle changes, specifically engaging in at least 2 hours of outdoor activities daily, with a minimum of 1 hour being effective for children who struggle to meet the full 2 hours [1] - The second method involves optical solutions, including OK lenses and certain functional glasses, which should be used under medical guidance [1] - The third method includes pharmacological options, such as low-concentration atropine, which must also be used according to a doctor's advice [1]

Core Insights - The potential harm of prolonged screen exposure on children's visual health has become increasingly prominent, leading to a surge in the children's lutein market as parents seek to protect their children's eyesight [1] - Some brands have been found to engage in misleading marketing practices regarding lutein products, suggesting efficacy in myopia prevention despite a lack of scientific evidence [2][14] Group 1: Market Dynamics - The children's lutein market is experiencing rapid growth due to rising awareness among parents about the importance of eye health [1] - Brands like GreenLife and NaturElan are still implicated in marketing practices that create anxiety and imply efficacy in myopia prevention, despite regulatory scrutiny [2][11] Group 2: Regulatory Environment - Following previous reports, the brand Zanhua has made corrections by removing misleading claims and clarifying the lack of evidence supporting lutein's role in preventing or controlling myopia [2] - Legal experts emphasize that misleading advertising, especially using endorsements from medical professionals, can violate competition laws [2] Group 3: Scientific Consensus - Experts agree that while lutein is beneficial as an antioxidant and for retinal health, there is no conclusive evidence supporting its effectiveness in preventing or controlling myopia [14][15] - The primary causes of myopia are linked to excessive near work and not directly related to lutein intake, highlighting the need for balanced dietary habits and proper eye care practices [14][15]

对于家里经济条件一般的家庭长大的人来说，比如我，很多令人习以为常的 “常识” 是从二十多岁开始才知道的比如，牙齿不齐是需要去整牙的，脊柱侧弯是需要去矫正的，轻度的近视在青少年阶段用角膜塑形镜是可以很大程度延缓近视度数加深的身体健康的养护和矫正，都是只有在 18 岁以下的黄金时期效率最高。再比如多语言环境，人年纪越小学语言越容易,并且多语言环境能促进大脑发育哪怕现在已经在做这些矫正项目让自己更健康，开始学一些小语种，可能也是有点追求完美主义，偶尔深夜想到这些还是会有遗憾，碍于客观的条件没能在最正确的时候做最正确的事，到了一把年纪了才知道补救贫穷局限了视野和认知，但感谢过去的贫穷让人更知道机会可贵，错过好的 timing 是多么可惜的事。和投资一样，在正确的时间做正确的事，举例就是在 early stage 开始玩 sol meme，随便买什么，大多都去了 100M，而到了下行期才开始玩 sol meme 扫链，10M 都难 ...

Core Insights - The overall myopia rate among children and adolescents in China reached 51.9% in 2022, with specific rates of 14.5% for 6-year-olds, 36% for elementary school students, 71.6% for middle school students, and 81% for high school students [2] Company Strategy - The company aims to raise awareness of its treatment plan to over 20 million people and ensure that over 1 million children receive timely and appropriate medication this year [2] - The company will implement a comprehensive multi-channel sales strategy, focusing on collaboration with retail channels and continuing academic promotion to build a network for myopia prevention and control [2]

Core Viewpoint - Mingyue Lens, a leading lens brand in China, collaborates with Qianye Glasses to launch a campus public welfare campaign aimed at promoting vision health among children and adolescents, addressing the rising myopia rates in the country [1][5][8] Group 1: Campaign Overview - The campaign titled "Climbing to the Peak and Building Dreams for a Voyage" involves sharing learning experiences and myopia prevention knowledge with students in Chongqing [1] - Tsinghua University student leader Zhang Zhiyuan participated in the event, providing practical study techniques and encouraging students to adopt healthy eye care practices [1][3] Group 2: Myopia Statistics and Importance - According to the National Health Commission, the overall myopia rate among children and adolescents in China is projected to reach 52.7% by 2024, indicating that one in two students is affected [5] - The significance of myopia prevention is underscored by the alarming statistics, prompting initiatives like the public welfare campaign [5] Group 3: Product Offering - Mingyue Lens offers the "Mingyue Easy Control Lens," designed specifically for Chinese children's eye habits, balancing prevention effectiveness and comfort [5] - Clinical trials conducted by Zhongshan Ophthalmic Center and Tianjin Eye Hospital show that the lens has a myopia progression control effectiveness rate of 73.82%, with results published in the international journal "Ophthalmology" [5] Group 4: Social Responsibility - As a national brand, Mingyue Lens emphasizes its social responsibility by promoting myopia prevention awareness across the country, advocating for the protection of children's vision as a means to secure a brighter future [8]

Core Viewpoint - The Ministry of Education, in collaboration with the National Health Commission and the National Disease Control Bureau, has issued a notification aimed at preventing myopia in children by promoting the preservation of hyperopia reserves through various measures [1][2]. Group 1: Policy Recommendations - The notification suggests comprehensive measures based on age groups, recommending that children aged 0-3 should avoid screens and ensure over 10 hours of sleep daily [1]. - For preschool children aged 3-6, outdoor play is emphasized, with a strong recommendation to limit screen time and avoid early academic pressure [1]. - Primary schools are advised to implement physical exercise plans that align with children's physical development, ensuring at least 2 hours of outdoor activity daily to foster good eye habits [1]. Group 2: Health Monitoring and Management - The notification mandates regular eye health checks, with medical institutions required to conduct refraction screenings to monitor children's hyperopia reserves [2]. - Primary schools must implement a bi-semester vision monitoring system to track students' vision and hyperopia reserve trends, providing timely feedback to parents [2]. - There is an emphasis on early detection of myopia risks, with recommendations for parents to seek professional evaluations for children showing abnormal vision indicators or insufficient hyperopia reserves [2].

Core Insights - The launch of the "National Vision Health Report (2026 Edition)" was officially initiated at the 8th China International Import Expo, led by Professor Li Ling from Peking University Health Development Research Center and supported by EssilorLuxottica [1][3] Group 1: Vision Health Report - The first edition of the "National Vision Health Report" was published in 2016, marking it as China's first systematic research white paper on vision health, which has since elevated myopia prevention to a national strategy [3][4] - The new version will deepen the focus on myopia prevention among youth and expand to "lifecycle vision health," leveraging successful experiences in myopia prevention to enhance system construction through policy and technology [3][4] Group 2: Collaboration and Initiatives - EssilorLuxottica announced support for the Shanghai Eye Disease Prevention and Treatment Center to launch the national health industry standard "Technical Guidelines for Graded and Classified Prevention and Treatment of Myopia in Children and Adolescents" [3][4] - Last year, EssilorLuxottica provided over 8,000 lenses to support a school-based myopia intervention project in Shanghai, which is part of the city's three-year action plan to strengthen public health systems [4]

Core Viewpoint - The stock price of Zhaoke Ophthalmology (06622) experienced significant volatility after reaching a peak of HKD 4.60 on August 18, 2023, marking a year-to-date increase of 283.33%. However, the stock has since entered a downward trend, with a cumulative decline of 30% over the following two and a half months, despite a recent milestone in the approval process for its key product, NVK002 [1][4][6]. Group 1: Stock Performance - Zhaoke Ophthalmology's stock price surged to a peak of HKD 4.60, reflecting a year-to-date increase of 283.33% [1] - Following the peak, the stock entered a downward trend characterized by "nine consecutive declines" and "ten consecutive declines," resulting in a cumulative drop of 30% [1] - On October 22, the stock saw a brief increase of 3.58% after the ANDA application for NVK002 was fully approved, but this gain was quickly reversed with a subsequent drop of 4.72% the following day [2][4] Group 2: Financial Performance - For the first half of 2023, Zhaoke Ophthalmology reported revenue of HKD 15.803 million, a year-on-year decline of 68.25%, and a net loss of HKD 117 million, an increase of 53.85% compared to the previous year [4] - The significant revenue drop was primarily due to a one-time licensing income of HKD 33.5 million in the previous year, which inflated the revenue base [4] - After adjusting for this one-time income, the product revenue for the current period was approximately HKD 15.1 million, showing only a slight decline from HKD 15.6 million in the same period last year [4] Group 3: Product Development and Market Potential - Zhaoke Ophthalmology's NVK002, a low-concentration atropine eye drop, has made significant progress, with its ANDA application accepted by the National Medical Products Administration of China [4][5] - The company is currently the only one in China with two concentrations of atropine eye drops under regulatory review, indicating a strong competitive position [5] - The potential market for myopia control in China is substantial, with approximately 700 million myopic patients, including 163 million children and adolescents who could benefit from NVK002 [5] - According to estimates, the myopia prevention market could reach HKD 210 billion by 2030, with a compound annual growth rate of approximately 13.7% [5] Group 4: Market Sentiment and Future Outlook - Following a significant price increase, the stock has shown signs of consolidation, with a current PB ratio of 0.92, well below the industry average of 3.15 [3] - The stock has experienced a "price flat, volume shrinking" phenomenon, indicating a potential stabilization at lower price levels [15] - Recent trading activity suggests that the stock may be nearing a bottom, with a potential for upward momentum if trading volume increases [15]

Core Viewpoint - The stock price of Zhaoke Ophthalmology (06622) experienced significant volatility after reaching a peak of HKD 4.60 on August 18, 2023, marking a year-to-date increase of 283.33%. However, the stock has since declined by approximately 30% over the following two and a half months, despite a recent milestone in the approval process for its key product, NVK002 [1][4][6]. Group 1: Stock Performance - Zhaoke Ophthalmology's stock price surged to a high of HKD 4.60, reflecting a year-to-date increase of 283.33% [1] - Following the peak, the stock entered a downward trend, experiencing a "slow knife" decline with a cumulative drop of 30% over two and a half months [1][2] - On October 22, the stock saw a brief increase of 3.58% after the ANDA application for NVK002 was fully approved, but this gain was quickly reversed with a subsequent drop of 4.72% the next day [2][6] Group 2: Financial Performance - For the first half of 2025, Zhaoke Ophthalmology reported revenue of HKD 15.803 million, a decline of 68.25% year-on-year, and a net loss of HKD 117 million, widening by 53.85% [4] - The revenue drop was primarily due to a one-time licensing income of HKD 33.5 million in the previous year, which inflated the revenue base [4] - Excluding this factor, product revenue was approximately HKD 15.1 million, showing only a slight decline from HKD 15.6 million in the same period last year [4] Group 3: Product Development - Zhaoke Ophthalmology's NVK002, a low-concentration atropine eye drop for myopia control, has made significant progress, with its ANDA application accepted by the National Medical Products Administration [4][5] - The company is the only one in China with two concentrations of atropine eye drops under regulatory review, indicating a strong market position [5] - The global myopia control market is projected to reach HKD 210 billion by 2030, with a compound annual growth rate of approximately 13.7% [5] Group 4: Market Dynamics - The current PB valuation of Zhaoke Ophthalmology is 0.92, significantly lower than the industry average of 3.15, indicating potential undervaluation [3] - The market for low-concentration atropine eye drops is currently limited, with only one competitor, suggesting a favorable competitive landscape for NVK002 [5] - Recent trading patterns indicate a consolidation phase, with a significant portion of the stock's average cost now at HKD 3.24, suggesting improved control by major investors [12][15]